| Literature DB >> 22873637 |
Phonthep Angsuwatcharakon1, Rungsun Rerknimitr, Wiriyaporn Ridtitid, Pradermchai Kongkam, Sahadol Poonyathawon, Yuwadee Ponauthai, Sakolkan Sumdin, Pinit Kullavanijaya.
Abstract
BACKGROUND: ERCP practically requires moderate to deep sedation controlled by a combination of benzodiazepine and opiod. Propofol as a sole agent may cause oversedation. A combination (cocktail) of infused propofol, meperidine, and midazolam can reduce the dosage of propofol and we hypothesized that it might decrease the risk of oversedation. We prospectively compare the efficacy, recovery time, patient satisfactory, and side effects between cocktail and conventional sedations in patients undergoing ERCP.Entities:
Year: 2012 PMID: 22873637 PMCID: PMC3434082 DOI: 10.1186/1471-2253-12-20
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Patient Characteristics
| Gender (male/female) | 51/51 | 52/51 | 1.000 |
| Age (years) a | 57.27 ± 14.52 | 59.56 ± 13.65 | 0.246 |
| Type of ERCP | | | 0.877 |
| - No-therapy* | 17 (16.7%) | 20 (18.4%) | |
| - Therapy | 83 (81.4%) | 81 (78.6%) | |
| - Fail | 2 (1.9%) | 2 (1.9%) | |
| BMI a | 22.18 ± 3.62 | 23.06 ± 3.83 | 0.097 |
| ASA class | | | 0.630 |
| - I | 42 (41.2%) | 49 (47.6%) | |
| - II | 49 (48%) | 43 (41.7%) | |
| - III | 11 (10.8%) | 11 (10.7%) |
a Data given as mean ± SD.
*No-therapy = cholangiogram and pancreatogram were obtained by contrast injection and no treatment was required after the negative result of cholangio-pancreatogram.
Procedural Data
| Mean dosage (mg) a | | | N/A |
| - Meperidine | 58.33 ± 24.46 | 25 | |
| - Midazolam | 6.81 ± 2.12 | 2.5 | |
| - Propofol | 0 | 172.08 ± 92.15 | |
| Dosage (mg/kg/hr) a | | | N/A |
| - Meperidine | 2.42 ± 2.58 | 1.06 ± 0.60 | |
| - Midazolam | 0.29 ± 0.36 | 0.11 ± 0.06 | |
| - Propofol | 0 | 6.18 ± 3.0 | |
| Indications for ERCP | | | 0.621 |
| - CBD stone | 51 (50.0%) | 53 (51.5%) | |
| - Benign biliary stricture | 7 (6.9%) | 10 (9.7%) | |
| - Malignant biliary stricture | 28 (27.4%) | 20 (19.4%) | |
| - Pancreatic therapy | 5 (4.9%) | 8 (7.8%) | |
| - Others | 11 (10.8%) | 12 (11.6) | |
| Time to intubation (min) a | 3.10 ± 1.86 | 3.68 ± 2.38 | 0.053 |
| Duration (min) a | 31.60 ± 17.56 | 27.88 ±14.38 | 0.099 |
a Data given as mean ± SD.
Cardiovascular and respiratory parameters
| Baseline SBP (mmHg)a | 137.2 ± 22.1 | 134.2 ± 19.1 | 0.309 |
| Mean% decrease of SBPa from baseline | 16.0 ± 10.5 | 17.2 ± 11.9 | 0.442 |
| SBP decrease ≥25% from baseline (% of patients) | 22.5 | 26.2 | 0.541 |
| SBP <90 mmHg (% of patients) | 4.9 | 13.6 | 0.057 |
| Baseline heart rate (HR/min) a | 86.0 ± 14.8 | 85.7 ± 15.1 | 0.867 |
| Mean% decrease of HR from baseline a | 12.5 ± 11.3 | 14.1 ± 12.3 | 0.333 |
| HR decrease ≥25% from baseline (% of patients) | 17.6 | 23.3 | 0.316 |
| Bradycardia (% of patients) | 0 | 1 | 1.000b |
| Apnea | 0 | 0 | |
| Baseline SpO2 (%)a | 98.5 ± 1.5 | 97.8 ± 2.9 | 0.052 |
| Greatest decline of SpO2 from baseline a | 6.7 ± 6.1 | 8.7 ± 6.9 | 0.026 |
| SpO2 <90% (% of patients, any episodes) | 31.4 | 58.3 | <0.001 |
| SpO2 <85% (% of patients, any episodes) | 1.0 | 8.7 | 0.019b |
a Data given as mean ± SD, b Fisher’s exact test.
Recovery parameters
| Recovery time (min) | 12.89 ± 12.87 | 9.67 ± 4.86 | 0.045 |
| Conscious score at 15 min | 9.73 ± 0.45 | 9.85 ± 0.53 | 0.102 |
| Conscious score at 30 min | 9.95 ± 0.21 | 9.99 ± 0.10 | 0.157 |
| Conscious score at 45 min | 9.99 ± 0.11 | 10.00 ± 0.00 | 0.320 |
| Conscious score at 60 min | 9.99 ± 0.11 | 10.00 ± 0.00 | 0.320 |
All data given as mean ± SD.
Patient tolerance and satisfaction
| Discomfort (Median; inter-quartile) | 10 (10, 20) | 10 (0, 20) | 0.006a |
| Gagging (Median; inter-quartile) | 10 (10, 20) | 10 (0, 20) | 0.003a |
| Satisfaction | 87.6 ± 9.6 | 93.1 ± 9.1 | <0.001 |
a Mann–Whitney U test.